NVS Jan 2025 92.500 call
| Previous close | 8.45 |
| Open | 8.55 |
| Bid | 8.10 |
| Ask | 8.30 |
| Strike | 92.50 |
| Expiry date | 2025-01-17 |
| Day's range | 8.45 - 8.59 |
| Contract range | N/A |
| Volume | |
| Open interest | 63 |
ZacksExploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of Novartis (NVS) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
GlobeNewswireNovartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of the ALITHIOS open-label extension study1Similar efficacy outcomes were demonstrated in a separate analysis of continuous Kesimpta treatment for up to six years in the overall ALITHIOS study population2 Switch from teriflunomide to Kesimpta resulted in significant improvements across several efficacy o
ZacksNovartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.
